Logo

Henlius Receives NMPA's IND Approval for its HLX13 (biosimilar- ipilimumab)

Share this

Henlius Receives NMPA's IND Approval for its HLX13 (biosimilar- ipilimumab)

Shots:

  • The approval follows the trials which involves assessing of HLX13 vs originator ipilimumab to evaluate its pharmacology- pharmacokinetics and toxicokinetics profiles- immunogenicity- and toxicity
  • The study resulted in biosimilarity data in terms of in vivo and in vitro pharmacology- PK- toxicokinetics- immunogenicity and toxicity characteristics
  • HLX13 is a recombinant anti-CTLA-4 fully human mAb injection resulting in  T cell activation in anti-tumour immune response and is developed under Chinese Biosimilar Guidelines approved for unresectable or metastatic melanoma- advanced RCC- MSI-H or dMMR Mcc and adjuvant treatment of melanoma

Click here to read full press release/ article | Ref: Henlius | Image: Twitter


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions